KMTS Share Price Performance
US$25.64
9.50 (58.86%)
12.0% undervalued intrinsic discount
US$29.14
Fair Value
Price US$25.64
AnalystConsensusTarget US$29.14
AnalystLowTarget US$28.00
AnalystHighTarget US$32.00
Fair ValueUS$29.14
Share Pricen/a
Kestra Medical Technologies, Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
KMTS Community Narratives
AN
Fair Value
·Fair Value US$29.14 12.0% undervalued intrinsic discount
Wearable Defibrillator Underpenetration Will Drive Long-Term Expansion In Cardiac Protection Adoption
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$28 8.4% undervalued intrinsic discount
Cardiac Recovery Catalysts Will Shape Guideline Adoption And Margin Progress Over The Long Term
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$32 19.9% undervalued intrinsic discount
Wearable Cardiac Protection Tailwinds Will Drive Stronger Market Adoption Over The Next Decade
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Cardiac Recovery Catalysts Will Shape Guideline Adoption And Margin Progress Over The Long Term
Kestra rents wearable heart defibrillators to protect people at risk of sudden cardiac arrest at home, but wider use may depend on doctors and medical guidelines catching up. New studies, software updates, and broader insurance coverage could help, yet slow adoption and tricky payer negotiations may keep progress bumpy.Read more
AN
US$28
8.4% undervalued intrinsic discount
Fair Value
Profit Margin
11.46%
Future PE
75.76x
Price in 2029
US$34.33
Wearable Cardiac Protection Tailwinds Will Drive Stronger Market Adoption Over The Next Decade
Doctors are paying more attention to the danger window after a heart event, and that could push more patients to use Kestra’s wearable defibrillator during recovery. The upside hinges on whether its lower-nuisance alerts, broader insurance coverage, and bigger sales reach can beat an entrenched rival—before ongoing losses force more fundraising.Read more
AN
US$32
19.9% undervalued intrinsic discount
Fair Value
Profit Margin
11.78%
Future PE
84.16x
Price in 2029
US$39.44
Wearable Defibrillator Underpenetration Will Drive Long-Term Expansion In Cardiac Protection Adoption
Catalysts About Kestra Medical Technologies Kestra Medical Technologies develops and leases the ASSURE wearable cardioverter defibrillator system to protect high risk cardiac patients during recovery and treatment optimization. What are the underlying business or industry changes driving this perspective?Read more
AN
US$29.14
12.0% undervalued intrinsic discount
Fair Value
Profit Margin
12.91%
Future PE
87.16x
Price in 2028
US$36.43
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
KMTS: Future Algorithm And Prescription Momentum May Support Undervalued Shares
Fair Value: US$28 8.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KMTS: Revenue Momentum And Clinical Data Will Support Bullish 2027 Outlook
Fair Value: US$32 19.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Wearable Defibrillator Underpenetration Will Drive Long-Term Expansion In Cardiac Protection Adoption
Fair Value: US$29.14 12.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Kestra Medical Technologies, Ltd. Key Details
Last Reported Earnings
Apr 30, 2026
Next Reporting Earnings
n/a
- -2.25
- 51.37%
- -138.36%
- 16.4%
About KMTS
- Founded
- 2014
- Employees
- 443
- CEO
- WebsiteView website
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. Its platform provides ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected; digital patient engagement and clinical workflow solutions designed to improve patient adherence, support care coordination, and provide actionable clinical insights throughout the recovery process; and integrated platform generates continuous cardiac rhythm data and clinically actionable insights. Kestra Medical Technologies, Ltd. was founded in 2014 and is based in Kirkland, Washington.
